Investor Presentaiton slide image

Investor Presentaiton

Product Superior Treatment to Blockbusters FB825 ONENESS Atopic dermatitis, Asthma Dupixent DUPIXENT (dupilumab) 300-2- DUPIXENT (dupilumab) Atopic dermatitis, Asthma RINVOQ RINVOG ONENESS Indication Administration SC Dose 13 doses/ year (every 4 weeks) Side effect No major side effects N/A Cost Target Cεmx N/A 2020 Global sales SC Rheumatoid arthritis, Atopic dermatitis Oral 26 doses/year (every 2 weeks) 365 tablets / year (daily dose) Allergic reactions/ eye problems Blood vessel inflammation Cold sores US$ 1,555 dose US$ 40,430 / year IL-4Ra US$ 3.5bn (AD approved in 2017, Asthma approved in 2018) 1 htps://icer.org/news-insights/press-releases/jak_inhibitor_evidence_report Common side effects: nausea, headache, and chest infections. Black-box Warning: "increased risk of serious infections, malignancy, and thrombosis" US$ 59,860 / year (upadacitinib's annual list price for RA¹) JAK1 US$ 0.7bn (RA only, approved in 2019) |20
View entire presentation